Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

ginning at 8 P.M. EDT. Access numbers for this replay are 888-203-1112 (U.S./Canada) and 719-457-0820 (international); participant code 4106309.

Amicus' press releases are available at http://www.amicustherapeutics.com

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera for the treatment of Gaucher disease. The Company recently completed Phase I clinical trials of AT2220 for the treatment of Pompe disease.

Forward-Looking Statements

This Press release contains and the accompanying conference call will contain "forward-looking statements" within the meaning of Section 21E of the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should" and "could," and similar expressions or words identify forward-looking statements. Examples of such statements include: (i) statements regarding the goals and expected timing of clinical studies, including the effect of the completion of the Phase 2 clinical trial for Amigal for the treatment of Fabry disease, the timing and design of Phase 3 clinical development for Amigal, the Phase 2 clinical trials for Plicera for the treatment of Gaucher disease, the effect of
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)...   Synageva BioPharma Corp. (NASDAQ: ... products for rare disorders, today reported 2014 full ... key objectives, and financial guidance.  Synageva,s management team ... p.m. EST to review the financial results and ... today,s call by telephone, please dial (877) 445-4603 ...
(Date:2/26/2015)... Fla. , Feb. 26, 2015 DuPont ... growth priorities driven by key research advancements and product ... at today,s Bank of America Merrill Lynch 2015 Global ... the challenge of building grain supplies the last two ... continue at the pace of the last decade, when ...
(Date:2/26/2015)... Calif. , Feb. 26, 2015  NuGene ... age-defying aesthetic products for skin and hair rejuvenation, ... Relations as agency of record for investor relations ... to improve our distribution, sales and diversification strategies ... to current and prospective shareholders," stated Ali Kharazmi ...
(Date:2/26/2015)... February 26, 2015 The Pittcon ... at the Ernest N. Morial Convention Center in ... as of February 19, 2015) displaying products and ... academic, and government labs. The Exposition will offer ... not limited to, analytical chemistry; drug discovery; nanotechnology; ...
Breaking Biology Technology:Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 2DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 3DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 4DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 5NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 2NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 3Pittcon 2015 Announces Exposition Highlights 2
... Record, a biophysical chemist at the University of Wisconsin-Madison, ... by the Biophysical Society, a 7,000-member U.S. organization that ... chemistry and biochemistry, Record hopes that the new honor ... extramural funding for his research. , ,A UW-Madison faculty ...
... Wis. -- Established and emerging biotech companies in ... industry at the upcoming Wisconsin Biotechnology and Medical ... held Oct. 14, at the Olympia Resort in Oconomowoc. ... to encourage the civic and business leaders of both ...
... . - The Medical College of Wisconsin has ... Center for Medical Countermeasures against Radiation, an effort to take ... damaged by radiation. , ,The institute is one of seven ... and Infectious Diseases (NIAID) to establish a plan for ...
Cached Biology Technology:State of biotech, medical device sector is focus of upcoming conference 2Medical College getting $18.1 million to study radiation damage treatments 2
(Date:2/5/2015)... , Feb. 5, 2015  Marken is starting ... company and has launched a new marketing campaign to ... Organization (CLO).  The new campaign focuses on First ... protocol and shipments. The first headline in ... aligns Marken,s priorities with its client,s priorities. Marken recognizes ...
(Date:2/5/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce market, ... Online CEO Conference on January 29 th at ... , CEO of NXT-ID will present and host a ... smart wallet and its full suite of biometric technologies. ...
(Date:1/22/2015)... Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to ... State of Washington,s Department of Licensing, in ... central issuance system for driver,s licenses and identification cards to ... and development will start in January 2015, with enrollment and ...
Breaking Biology News(10 mins):Marken Launches New Patient-Centric Campaign 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3Valid USA Signs Contract For Washington Driver's License Issuance 2
... published by Pensoft reported a substantial growth in 2011, ... jubilee 150th issue, By the end of November 2011, the ... compare with 4,962 pages and 180 articles in 2010). Since ... than 19,000 pages and 780 articles of valuable information on ...
... single patient population study to date on a ... cava (IVC) filtersdevices used to keep blood clots ... is important for individuals with IVC filters and ... Society of Interventional Radiology, a national organization of ...
... the Swedish medical university Karolinska Institutet and the University of ... defense mechanism against cancer. The VCP/p97 complex is best known ... a type of familial dementia and ALS. In a novel ... an important role in regulating the recruitment of the tumor ...
Cached Biology News:Growth through innovations and open access: The journal ZooKeys on point for digital taxonomy 2IVC filters: Society of Interventional Radiology leads in patient care, safety, research 2IVC filters: Society of Interventional Radiology leads in patient care, safety, research 3An unexpected player in a cancer defense system 2
... Manual Cycle Sequencing Kit is designed to ... high-resolution fluorescence scanners. Sequencing reactions involve a ... electrophoresis and scanning of the gel to ... kit components have been optimized for sequencing ...
... Green II RNA gel stain is a ... fluorescence when bound to RNA and low background ... either formaldehyde/agarose or polyacrylamide gels using laser scanners ... minigels. A 500 µL unit size (S-7564) and ...
... Custom DNA microarrays designed for your ... and powerful Paraflo microfluidic synthesis platform. Thousands ... on-chip and LC Sciences can provide assistance ... available as part of our comprehensive Custom ...
... for DNA aptamer screening and binding optimization ... Paraflo microfluidic on-chip synthesis platform. These microarrays ... DNA/RNA Aptamer Microarray Service. Probe ... contains greater than 1500 known aptamer sequences. ...
Biology Products: